Skip to Content

Proposed Rule

Amendments to General Regulations of the Food and Drug Administration

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 73984

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Proposed rule.

SUMMARY:

The Food and Drug Administration (FDA) is proposing to amend certain of its general regulations to include tobacco products, where appropriate, in light of FDA's authority to regulate these products under the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act). With these amendments, tobacco products will be subject to the same general requirements that apply to other FDA-regulated products. This proposed rule is a companion document to the direct final rule published elsewhere in this issue of the Federal Register.

DATES:

Submit either electronic or written comments by February 14, 2011.

ADDRESSES:

You may submit comments, identified by Docket No. FDA-2010-N-0560 and/or RIN number 0910-AG55, by any of the following methods:

Electronic Submissions

Submit electronic comments in the following way:

Written Submissions

Submit written submissions in the following ways:

  • FAX: 301-827-6870.
  • Mail/Hand delivery/Courier (for paper, disk, or CD-ROM submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Instructions: All submissions received must include the Agency name and docket number and Regulatory Information Number (RIN) for this rulemaking. All comments received may be posted without change to http://www.regulations.gov, including any personal information provided. For additional information on submitting comments, see the “Comments” heading of the SUPPLEMENTARY INFORMATION section of this document.

Docket: For access to the docket to read background documents or comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Gerie A. Voss, Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., rm. 240G, Rockville, MD 20850, 1-877-CTP-1373, gerie.voss@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Why is this rule being issued as a companion proposed rule?

This proposed rule is a companion to the direct final rule regarding amendments to general regulations that is published in the final rules section of this issue of the Federal Register. The direct final rule and this companion proposed rule are identical. This companion proposed rule provides the procedural framework to finalize the rule in the event that the direct final rule receives any significant adverse comment and is withdrawn. We are publishing the direct final rule because the rule is noncontroversial, and we do not anticipate that it will receive any significant adverse comments. If no significant adverse comment is received in response to the direct final rule, no further action will be taken related to this proposed rule. Instead, we will publish a confirmation document within 30 days after the comment period ends confirming when the direct final rule will go into effect.

If we receive any significant adverse comment regarding the direct final rule, we will withdraw the direct final rule within 30 days after the comment period ends and proceed to respond to all of the comments under this companion proposed rule using usual notice-and-comment rulemaking procedures under the Administrative Procedure Act (APA) (5 U.S.C. 553). The comment period for this companion proposed rule runs concurrently with the direct final rule's comment period. Any comments received under this companion proposed rule will also be considered as comments regarding the direct final rule.

A significant adverse comment is defined as a comment that explains why the rule would be inappropriate, including challenges to the rule's underlying premise or approach, or would be ineffective or unacceptable without a change. In determining whether an adverse comment is significant and warrants terminating a direct final rulemaking, we will consider whether the comment raises an issue serious enough to warrant a substantive response in a notice-and-comment process in accordance with the APA. Comments that are frivolous, insubstantial, or outside the scope of the rule will not be considered significant or adverse under this procedure. For example, a comment recommending an additional change to the rule will not be considered a significant adverse comment, unless the comment states why the rule would be ineffective without the additional change. In addition, if a significant adverse comment applies to part of a rule and that part can be severed from the remainder of the rule, we may adopt as final those parts of the rule that are not the subject of a significant adverse comment.

You can find additional information about FDA's direct final rulemaking procedures in the guidance document entitled “Guidance for FDA and Industry: Direct Final Rule Procedures” (62 FR 62466, November 21, 1997). This guidance document may be accessed at http://www.fda.gov/​RegulatoryInformation/​Guidances/​ucm125166.htm.

II. What is the background of the rule?

The Tobacco Control Act was enacted on June 22, 2009, amending the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and providing FDA with the authority to regulate tobacco products (Pub. L. 11-31; 123 Stat. 1776). In enacting the Tobacco Control Act, Congress sought to ensure that FDA had authority to provide effective oversight and to impose appropriate regulatory controls on tobacco products. In order to effectuate these purposes, FDA is amending several provisions of its general regulations to reflect the Agency's new authority and mandate regarding tobacco products.

III. What does this companion proposed rule do?

FDA proposes to make the following amendments to its existing general regulations, reflecting the Agency's authority over tobacco products under the Tobacco Control Act:

1. Revising 21 CFR 1.1(b) to ensure the applicability of definitions contained in the Tobacco Control Act;

2. Removing the reference to “package” in 21 CFR 1.1(c), as this definition now also is covered by the Tobacco Control Act and is no longer provided solely by the Fair Packaging and Labeling Act;

3. Revising 21 CFR 1.20 to exclude from this definition of “package” the Start Printed Page 73985term “package” as defined in section 900(13) of the Tobacco Control Act (21 U.S.C. 387q(13));

4. Adding paragraph (f) to 21 CFR 14.55 to identify the Tobacco Products Scientific Advisory Committee as a permanent statutory advisory committee; and

5. Adding paragraph (j) to 21 CFR 17.1 and revising 21 CFR 17.2 to reflect FDA's authority to impose civil monetary penalties on tobacco-related violations.

IV. What is the legal authority for this proposed rule?

FDA is issuing this proposed rule under provisions of the FD&C Act, as amended by the Tobacco Control Act (21 U.S.C. 321, 331, 333, 387, 387a, and 387q).

V. What is the environmental impact of this proposed rule?

The Agency has determined under 21 CFR 25.30(h) and (i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

VI. What is the economic impact of this proposed rule?

FDA has examined the impacts of the proposed rule under Executive Order 12866 and the Regulatory Flexibility Act (5 U.S.C. 601-612), and the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). The Agency believes that this proposed rule is not a significant regulatory action under the Executive order.

The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Because the proposed rule would not impose any new requirements on tobacco product manufacturers, retailers, or distributors, the Agency proposes to certify that the rule will not have a significant economic impact on a substantial number of small entities.

Section 202(a) of the Unfunded Mandates Reform Act of 1995 requires that agencies prepare a written statement, which includes an assessment of anticipated costs and benefits, before proposing “any rule that includes any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted annually for inflation) in any one year.” The current threshold after adjustment for inflation is $135 million, using the most current (2009) Implicit Price Deflator for the Gross Domestic Product. FDA does not expect this proposed rule to result in any 1-year expenditure that would meet or exceed this amount.

VII. Paperwork Reduction Act of 1995

FDA concludes that the regulatory revisions and amendments identified in this document are not subject to review by the Office of Management and Budget because they do not constitute a “collection of information” under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

VIII. What are the federalism impacts of this proposed rule?

FDA has analyzed this proposed rule in accordance with the principles set forth in Executive Order 13132. FDA has determined that the proposed rule, if finalized, would not contain policies that would have substantial direct effects on the States, on the relationship between the National Government and the States, or on the distribution of power and responsibilities among the various levels of government. Accordingly, the Agency has concluded that the proposed rule does not contain policies that have federalism implications as defined in the Executive order and, consequently, a federalism summary impact statement is not required.

IX. How do you submit comments on this proposed rule?

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Start List of Subjects

List of Subjects

End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, it is proposed that 21 CFR parts 1, 14, and 17 be amended to read as follows:

Start Part

PART 1—GENERAL ENFORCEMENT REGULATIONS

1. The authority citation for part 1 is revised to read as follows:

Start Authority

Authority: 15 U.S.C. 1453, 1454, 1455; 19 U.S.C. 1490, 1491; 21 U.S.C. 321, 331, 333, 334, 335a, 343, 350c, 350d, 352, 355, 360b, 362, 371, 374, 381, 382, 387, 387a, 393; 42 U.S.C. 216, 241, 243, 262, 264.

End Authority

2. In § 1.1 revise paragraph (b); and in the first sentence of paragraph (c), remove “package in § 1.20 and of” to read as follows:

General.
* * * * *

(b) The definitions and interpretations of terms contained in sections 201 and 900 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321 and 387) shall be applicable also to such terms when used in regulations promulgated under that act.

3. Amend § 1.20 by revising the introductory text to read as follows:

Presence of mandatory label information.

Except as otherwise provided by section 900(13) of the Family Smoking Prevention and Tobacco Control Act (21 U.S.C. 387(13)) defining “package,” the term package means any container or wrapping in which any food, drug, device, or cosmetic is enclosed for use in the delivery or display of such commodities to retail purchasers, but does not include:

* * * * *
End Part Start Part

PART 14—PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE

4. The authority citation for part 14 continues to read as follows:

Start Authority

Authority: 5 U.S.C. App. 2; 15 U.S.C. 1451-1461, 21 U.S.C. 41-50, 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42 U.S.C. 201, 262, 263b, 264; Pub. L. 107-109; Pub. L. 108-155

End Authority

5. Amend § 14.55 by adding paragraph (f) to read as follows:

Start Printed Page 73986
Termination of advisory committees.
* * * * *

(f) The Tobacco Products Scientific Advisory Committee is a permanent statutory advisory committee established by section 917 of the Family Smoking Prevention and Tobacco Control Act (21 U.S.C. 387q) (Pub. L. 111-31) and is not subject to termination and renewal under paragraph (a) of this section.

End Part Start Part

PART 17—CIVIL MONEY PENALTIES HEARINGS

6. The authority citation for part 17 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 331, 333, 337, 351, 352, 355, 360, 360c, 360f, 360i, 360j, 371; 42 U.S.C. 262, 263b, 300aa-28; 5 U.S.C. 554, 555, 556, 557.

End Authority

7. Amend § 17.1 by adding paragraph (j) to read as follows:

Scope.
* * * * *

(j) Section 303(f) of the act authorizing civil money penalties for any person who violates a requirement of the Family Smoking Prevention and Tobacco Control Act which relates to tobacco products.

8. Revise § 17.2 to read as follows:

Maximum penalty amounts.

The following table shows maximum civil monetary penalties associated with the statutory provisions authorizing civil monetary penalties under the act or the Public Health Service Act.

Civil Monetary Penalties Authorities Administered by FDA and Adjusted Maximum Penalty Amounts

U.S.C. sectionFormer maximum penalty amount (in dollars) 1Assessment methodDate of last penalty figure or adjustmentAdjusted maximum penalty amount (in dollars)
21 U.S.C.
333(b)(2)(A)55,000For each of the first two violations in any 10-year period200860,000.
333(b)(2)(B)1,100,000For each violation after the second conviction in any 10-year period20081,200,000.
333(b)(3)110,000Per violation2008120,000.
333(f)(1)(A)16,500Per violation200816,500 (not adjusted).
333(f)(1)(A)1,100,000For the aggregate of violations20081,200,000.
333(f)(2)(A)55,000Per individual200860,000.
333(f)(2)(A)275,000Per “any other person”2008300,000.
333(f)(2)(A)550,000For all violations adjudicated in a single proceeding2008600,000.
333(f)(3)(A)10,000For all violations adjudicated in a single proceeding200710,000 (not adjusted).
333(f)(3)(B)10,000For each day the violation is not corrected after a 30-day period following notification until the violation is corrected200710,000 (not adjusted).
333(f)(4)(A)(i)250,000Per violation2007250,000 (not adjusted).
333(f)(4)(A)(i)1,000,000For all violations adjudicated in a single proceeding20071,000,000 (not adjusted).
333(f)(4)(A)(ii)250,000For the first 30-day period (or any portion thereof) of continued violation following notification2007250,000 (not adjusted).
333(f)(4)(A)(ii)1,000,000For any 30-day period, where the amount doubles for every 30-day period of continued violation after the first 30-day period20071,000,000 (not adjusted).
333(f)(4)(A)(ii)10,000,000For all violations adjudicated in a single proceeding200710,000,000 (not adjusted).
333(f)(9)(A)1 N/APer violation200915,000 (not adjusted).
333(f)(9)(A)N/AFor all violations adjudicated in a single proceeding20091,000,000 (not adjusted).
333(f)(9)(B)(i)(I)N/APer violation2009250,000 (not adjusted).
333(f)(9)(B)(i)(I)N/AFor all violations adjudicated in a single proceeding20091,000,000 (not adjusted).
333(f)(9)(B)(i)(II)N/AFor the first 30-day period (or any portion thereof) of continued violation following notification2009250,000 (not adjusted).
333(f)(9)(B)(i)(II)N/AFor any 30-day period, where the amount doubled for every 30-day period of continued violation after the first 30-day period20091,000,000 (not adjusted).
333(f)(9)(B)(i)(II)N/AFor all violations adjudicated in a single proceeding200910,000,000 (not adjusted).
333(f)(9)(B)(ii)(I)N/APer violation2009250,000 (not adjusted).
333(f)(9)(B)(ii)(I)N/AFor all violations adjudicated in a single proceeding20091,000,000 (not adjusted).
333(f)(9)(B)(ii)(II)N/AFor the first 30-day period (or any portion thereof) of continued violation following notification2009250,000 (not adjusted).
333(f)(9)(B)(ii)(II)N/AFor any 30-day period, where the amount doubled for every 30-day period of continued violation after the first 30-day period20091,000,000 (not adjusted).
333(f)(9)(B)(ii)(II)N/AFor all violations adjudicated in a single proceeding200910,000,000 (not adjusted).
333(g)(1)250,000For the first violation in any 3-year period2007250,000 (not adjusted).
333(g)(1)500,000For each subsequent violation in any 3-year period2007500,000 (not adjusted).
333 noteN/AFor the second violation (following a first violation with warning) within a 12-month period by a retailer with an approved training program2009250 (not adjusted).
333 noteN/AFor the third violation within a 24-month period by a retailer with an approved training program2009500 (not adjusted).
333 noteN/AFor the fourth violation within a 24-month period by a retailer with an approved training program20092,000 (not adjusted).
333 noteN/AFor the fifth violation within a 36-month period by a retailer with an approved training program20095,000 (not adjusted).
Start Printed Page 73987
333 noteN/AFor the six or subsequent violation within a 48-month period by a retailer with an approved training program200910,000 (not adjusted).
333 noteN/AFor the first violation by a retailer without an approved training program2009250 (not adjusted).
333 noteN/AFor the second violation within a 12-month period by a retailer without an approved training program2009500 (not adjusted).
333 noteN/AFor the third violation within a 24-month period by a retailer without an approved training program20091,000 (not adjusted).
333 noteN/AFor the fourth violation within a 24-month period by a retailer without an approved training program20092,000 (not adjusted).
333 noteN/AFor the fifth violation within a 36-month period by a retailer without an approved training program20095,000 (not adjusted).
333 noteN/AFor the six or subsequent violation within a 48-month period by a retailer without an approved training program200910,000 (not adjusted).
335b(a)275,000Per violation for an individual2008300,000.
335b(a)1,100,000Per violation for “any other person”20081,200,000.
360pp(b)(1)1,100Per violation per person20081,100 (not adjusted).
360pp(b)(1)330,000For any related series of violations2008355,000.
42 U.S.C.
263b(h)(3)11,000Per violation200811,000 (not adjusted).
300aa-28(b)(1)110,000Per occurrence2008120,000.
1 Maximum penalties assessed under The Family Smoking Prevention and Tobacco Control Act do not have a “former maximum penalty.”
Start Signature

Dated: November 23, 2010.

Leslie Kux,

Acting Assistant Commissioner for Policy.

End Signature End Part End Supplemental Information

[FR Doc. 2010-30040 Filed 11-29-10; 8:45 am]

BILLING CODE 4160-01-P